To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Actelion announces cost saving initiative to be implemented by the end of 2012
Initiative could result in a reduction of up to 135 positions
13-07-2012: Actelion announced that the company has launched a cost saving initiative as an integral part of its strategy for value creation outlined in early May 2012. The initiative will ensure that the company can fully capitalize on the significant growth opportunities in its core area of expertise of pulmonary arterial hypertension (PAH).
The cost saving initiative addresses several challenges facing the company, including the continued strength of the Swiss Franc, increased competition in the United States, and the difficult pricing and reimbursement environment in Europe.
In parallel, the company is also refocusing its Research and Development (R&D) activities towards orphan and specialty indications so as to generate - in the mid-term - additional specialty franchises.
These steps ensure the availability of sufficient investment capacity to maximize the opportunities the company has created in the field of pulmonary arterial hypertension.
The refocusing of Actelion's R&D efforts is expected to result in lower and more targeted R&D spending. Following a portfolio review, those projects which are not in alignment with this strategy will be either stopped, or prepared for partnership or out-licensing.
Cost savings will start to take effect in the latter part of 2012 and accelerate in 2013. The refocusing of the pipeline will require a realignment of the organization.
The cost saving initiative is expected to result in a reduction of up to 135 positions in Research & Development and in administration. Approximately 115 positions could be impacted in Allschwil, Switzerland where these functions are predominantly located. Actelion's key global functions are - and will continue to be - headquartered in Switzerland.
Actelion is committed to minimizing the number of potential redundancies through natural attrition, early retirements and other such measures. The company has initiated a consultation process with employee representatives in Allschwil.
Upon completion of the consultation process, Actelion intends to implement a social plan and conclude the initiative before the end of 2012. Consequently a one-off restructuring charge - the size of which is still to be determined, in part, upon conclusion of employee consultations - will be included in the 2012 financial statements.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
- 1Pro Bono Bio Launches Flexiseq: A Novel Approach to the Treatment of Osteoarthritis
- 2Fighting listeria and other food-borne illnesses with nanobiotechnology
- 3Pharma’s New Hero: Supergenerics Save Money and Improve Drugs
- 4Researchers divide enzyme to conquer genetic puzzle
- 5Using human brain cells to make mice smarter
- 6Vivacta Initiates Development of Point of Care Test for Vitamin D
- 7A light switch inside the brain
- 8Rosetta Resolver® Gene Expression Data Analysis System licensed by Aventis Pharmaceuticals, Inc.
- 9New study confirms fungal infection of the foot is a risk factor for bacterial tissue infection of the leg
- 10Bayer’s Novel Anticoagulant Xarelto now also Approved in the EU
- Carl Zeiss Meditec improves its results in first six months of financial yea ...
- Evonik selects OPX Biotechnologies for joint development of bio-based chemicals
- Frost & Sullivan commends Merck Serono for its excellence in product differe ...
- SYGNIS reports results for the first quarter of 2013
- ZEISS presents half-year financial figures
